CLINICAL_TRIALS
trial_result
· 2024-11-20
Clinical Trial Update: Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies [Phase 1]
Summary
Phase 1 trial evaluating talimogene laherparepvec (T-VEC) for peritoneal surface malignancies has completed; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Dan Blazer III, M.D. | Conditions: Peritoneal Surface Malignancy | Phase 1 | Status: COMPLETED | Results posted: 2024-11-20